JP2019201631A - 治療用微小胞と幹細胞の合成 - Google Patents

治療用微小胞と幹細胞の合成 Download PDF

Info

Publication number
JP2019201631A
JP2019201631A JP2019011767A JP2019011767A JP2019201631A JP 2019201631 A JP2019201631 A JP 2019201631A JP 2019011767 A JP2019011767 A JP 2019011767A JP 2019011767 A JP2019011767 A JP 2019011767A JP 2019201631 A JP2019201631 A JP 2019201631A
Authority
JP
Japan
Prior art keywords
isoxazole
pyrrolo
carboxylic acid
dione
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019011767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019201631A5 (https=
Inventor
アシュラフ，ムハンマド
Ashraf Muhammad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019201631A publication Critical patent/JP2019201631A/ja
Publication of JP2019201631A5 publication Critical patent/JP2019201631A5/ja
Priority to JP2023126654A priority Critical patent/JP7837302B2/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0661—Smooth muscle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1329—Cardiomyocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019011767A 2018-01-26 2019-01-28 治療用微小胞と幹細胞の合成 Pending JP2019201631A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023126654A JP7837302B2 (ja) 2018-01-26 2023-08-03 治療用途のための微小胞および幹細胞組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/881,693 US20180273906A1 (en) 2014-04-17 2018-01-26 Microvesicle and stem cell compositions for therapeutic applications
US15/881,693 2018-01-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023126654A Division JP7837302B2 (ja) 2018-01-26 2023-08-03 治療用途のための微小胞および幹細胞組成物

Publications (2)

Publication Number Publication Date
JP2019201631A true JP2019201631A (ja) 2019-11-28
JP2019201631A5 JP2019201631A5 (https=) 2022-03-08

Family

ID=68725220

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019011767A Pending JP2019201631A (ja) 2018-01-26 2019-01-28 治療用微小胞と幹細胞の合成
JP2023126654A Active JP7837302B2 (ja) 2018-01-26 2023-08-03 治療用途のための微小胞および幹細胞組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023126654A Active JP7837302B2 (ja) 2018-01-26 2023-08-03 治療用途のための微小胞および幹細胞組成物

Country Status (2)

Country Link
US (2) US20180273906A1 (https=)
JP (2) JP2019201631A (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022080455A1 (ja) * 2020-10-14 2022-04-21 ダ・ヴィンチ ユニバーサル株式会社 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法
WO2023079655A1 (ja) * 2021-11-04 2023-05-11 株式会社リバティソリューション エクソソーム抽出方法
KR20230140140A (ko) * 2022-03-29 2023-10-06 박동선 Tsg101 단백질을 암호화하는 폴리뉴클레오티드가 도입된 줄기세포 및 이의 용도
JP2023145686A (ja) * 2018-01-26 2023-10-11 アシュラフ，ムハンマド 治療用途のための微小胞および幹細胞組成物
JP2023550453A (ja) * 2020-11-18 2023-12-01 富士フイルム株式会社 セクレトーム含有組成物の生成、並びにその使用及び分析方法
US12584906B2 (en) 2020-02-10 2026-03-24 Public University Corporation Nagoya City University Coating agent for inducing differentiation of pluripotent stem cells into brain microvascular endothelium-like cells and use thereof

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014197421A1 (en) 2013-06-05 2014-12-11 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
CA3202332A1 (en) 2015-12-07 2017-06-15 Agex Therapeutics, Inc. Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells
KR20180057546A (ko) * 2016-11-21 2018-05-30 성균관대학교산학협력단 지방줄기세포유래 엑소좀을 유효성분으로 포함하는 간 섬유증 예방 또는 치료용 조성물
CN112334190B (zh) * 2018-04-30 2024-09-20 儿童医学中心公司 间充质基质细胞外排体及其用途
CN109266603A (zh) * 2018-08-29 2019-01-25 浙江大学 一种提高心梗疗效的外泌体及应用
US12508325B2 (en) 2018-12-20 2025-12-30 Ohio State Innovation Foundation Compositions and methods for reprogramming diseased musculoskeletal cells
WO2020132161A1 (en) * 2018-12-21 2020-06-25 The Regents Of The University Of California Compositions and methods for treating hearing loss
CN114207110A (zh) * 2019-03-28 2022-03-18 Agex治疗公司 使用细胞外囊泡诱导的组织再生
KR20220039647A (ko) * 2019-04-03 2022-03-29 더 존스 홉킨스 유니버시티 골격근 줄기세포 생성 및 질환 치료를 위한 방법, 조성물 및 키트
US20220233604A1 (en) * 2019-05-15 2022-07-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating cardiomyocytes
CN110257333A (zh) * 2019-05-27 2019-09-20 江苏大学 一种神经干细胞微囊泡及其应用
CN110724665A (zh) * 2019-11-21 2020-01-24 西安外事学院 一种iPS细胞培养上清液及其制备方法和应用
WO2021114164A1 (zh) * 2019-12-12 2021-06-17 中国科学院深圳先进技术研究院 一种外泌体及其制备方法及应用
CN111961645A (zh) * 2020-09-01 2020-11-20 杭州优渡生物科技有限公司 一种高效扩增人表皮成纤维细胞的培养基
CN112608972B (zh) * 2020-12-21 2021-09-10 广东源心再生医学有限公司 Myog基因作为靶点在制备治疗心肌细胞凋亡相关的心血管疾病的药物中的应用
CN114645021A (zh) * 2020-12-21 2022-06-21 未来智人再生医学研究院(广州)有限公司 一种表达靶向cd47抑制因子的多能干细胞及其衍生物与应用
CN114657130A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达vegf-a靶向抑制因子的多能干细胞及其衍生物与应用
CN113209135B (zh) * 2021-04-23 2023-06-13 奥启(深圳)生物科技有限公司 一种用于延缓皮肤衰老的间充质干细胞外泌体制剂
CN113322226A (zh) * 2021-06-28 2021-08-31 华南理工大学 三维培养胚胎干细胞来源的外泌体及在制备治疗肝纤维化药物的应用
WO2023136313A1 (ja) * 2022-01-14 2023-07-20 国立大学法人大阪大学 肝機能障害を処置するための組成物
WO2023154466A1 (en) * 2022-02-11 2023-08-17 The University Of North Carolina At Chapel Hill Arylbenzoisoxazole compounds as ip6k and ipmk inhibitors and methods of use thereof
PL443827A1 (pl) * 2023-02-18 2024-08-19 Uniwersytet Jagielloński Sposób otrzymywania pęcherzyków zewnątrzkomórkowych (EVs) pochodzących z indukowanych pluripotencjalnych komórek macierzystych (iPSC) oraz ich zastosowanie
WO2025117472A1 (en) * 2023-11-30 2025-06-05 Immorta Bio, Inc. Treatment of heart failure using pluripotent stem cell derived cardiomyocytes and derivatives thereof
WO2025160404A1 (en) * 2024-01-26 2025-07-31 FUJIFILM Cellular Dynamics, Inc. Generation of secretome-containing compositions, and methods of using and analyzing the same
WO2025247999A1 (en) * 2024-05-30 2025-12-04 Conveyxo Method for the production of extracellular vesicles loaded with a molecule of interest and composition comprising such extracellular vesicles
EP4656187A1 (en) * 2024-05-30 2025-12-03 ConvEyXo Method for the production of extracellular vesicles loaded with a molecule of interest and composition comprising such extracellular vesicles
CN120131648B (zh) * 2025-03-06 2025-11-25 上海市重大传染病和生物安全研究院 一种hiv-1潜伏感染激活剂、药物及用途
CN120437124A (zh) * 2025-06-10 2025-08-08 南方医科大学 小分子isx-9在促进间充质干细胞成骨分化和骨损伤再生修复中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513482A (ja) * 2014-04-17 2017-06-01 アシュラフ, ムハンマドASHRAF, Muhammad 安全な治療のための化学的人工多能性幹細胞

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10443044B2 (en) 2014-04-17 2019-10-15 Ips Heart Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds
US20180273906A1 (en) 2014-04-17 2018-09-27 Muhammad Ashraf Microvesicle and stem cell compositions for therapeutic applications
WO2016108288A1 (ja) 2014-12-29 2016-07-07 国立大学法人京都大学 骨格筋前駆細胞の製造方法
WO2017196175A1 (en) 2016-05-12 2017-11-16 Erasmus University Medical Center Rotterdam A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513482A (ja) * 2014-04-17 2017-06-01 アシュラフ, ムハンマドASHRAF, Muhammad 安全な治療のための化学的人工多能性幹細胞

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEM CELLS INTERNATIONAL, vol. Vol.2017, Article ID 5785436, JPN7023000709, 15 October 2017 (2017-10-15), pages 1 - 14, ISSN: 0005168820 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023145686A (ja) * 2018-01-26 2023-10-11 アシュラフ，ムハンマド 治療用途のための微小胞および幹細胞組成物
JP7837302B2 (ja) 2018-01-26 2026-03-30 アシュラフ，ムハンマド 治療用途のための微小胞および幹細胞組成物
US12584906B2 (en) 2020-02-10 2026-03-24 Public University Corporation Nagoya City University Coating agent for inducing differentiation of pluripotent stem cells into brain microvascular endothelium-like cells and use thereof
WO2022080455A1 (ja) * 2020-10-14 2022-04-21 ダ・ヴィンチ ユニバーサル株式会社 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法
JP2025106562A (ja) * 2020-10-14 2025-07-15 ダ・ヴィンチ ユニバーサル株式会社 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法
JP2023550453A (ja) * 2020-11-18 2023-12-01 富士フイルム株式会社 セクレトーム含有組成物の生成、並びにその使用及び分析方法
WO2023079655A1 (ja) * 2021-11-04 2023-05-11 株式会社リバティソリューション エクソソーム抽出方法
KR20230140140A (ko) * 2022-03-29 2023-10-06 박동선 Tsg101 단백질을 암호화하는 폴리뉴클레오티드가 도입된 줄기세포 및 이의 용도
KR102816689B1 (ko) 2022-03-29 2025-06-02 박동선 Tsg101 단백질을 암호화하는 폴리뉴클레오티드가 도입된 줄기세포 및 이의 용도

Also Published As

Publication number Publication date
US20180273906A1 (en) 2018-09-27
JP2023145686A (ja) 2023-10-11
JP7837302B2 (ja) 2026-03-30
US20210054344A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
JP7837302B2 (ja) 治療用途のための微小胞および幹細胞組成物
Tomescot et al. Differentiation in vivo of cardiac committed human embryonic stem cells in postmyocardial infarcted rats
Li et al. The NADPH oxidase NOX4 drives cardiac differentiation: Role in regulating cardiac transcription factors and MAP kinase activation
CN104520422B (zh) 由人羊水来源的细胞生成功能性的和持久的内皮细胞
JP2019528736A (ja) ｍｏｄＲＮＡの細胞特異的発現
US10443044B2 (en) Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds
Zhang et al. Knockout of beta‐2 microglobulin reduces stem cell‐induced immune rejection and enhances ischaemic hindlimb repair via exosome/miR‐24/Bim pathway
Yu et al. Enhanced angiogenic potential of adipose-derived stem cell sheets by integration with cell spheroids of the same source
Xiao et al. Cardiopulmonary progenitors facilitate cardiac repair via exosomal transfer of miR‐27b‐3p targeting the SIK1‐CREB1 axis
US20220228120A1 (en) Cardiomyocyte Compositions and Use Thereof
CN113710258A (zh) Prpf31基因表达敲低提高体外分化的人细胞的存活
US20240392252A1 (en) Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds
JP2021528984A (ja) 成体幹細胞の拡大と誘導のインビトロでの誘発
US11821003B2 (en) Cardiogenic mesoderm formation regulators
US20160076001A1 (en) Chemically treated induced pluripotent stem cells for safe therapeutic applications
CA3133981A1 (en) Direct reprogramming of cardiac fibroblasts into cardiomyocytes using an endothelial cell transdifferentiation strategy
Lam Elucidating the Role of Pabpn1 in Alternative Polyadenylation During Satellite Cell Activation
Camberos The Hippo/Yap Signaling Pathway in Cardiovascular Repair
Chen Promoting heart regeneration via cardiomyocyte-specific OSKM-expression
JP2023550151A (ja) 幹細胞ニッチにおけるｈｉｐｐｏシグナル伝達を抑制することによる骨格筋再生の促進
Vicente Disclosing CCBE1 role in Cardiac Differentiation of Human Pluripotent Stem Cells
EP2830639A1 (en) Methods and compositions using fgf-8 to enhance cardiac regeneration and attenuate adverse cardiac remodeling
Iglesias-García Analysis of the regenerative potential of the induced pluripotent stem cells in a model of acute myocardial infarction in mice
García Analysis of the regenerative potential of the induced pluripotent stem cells in a model of acute myocardial infarction in mice
HK1209155B (en) Generation of functional and durable endothelial cells from human amniotic fluid-derived cells

Legal Events

Date Code Title Description
AA31 Notification that no translation was submitted

Free format text: JAPANESE INTERMEDIATE CODE: A243631

Effective date: 20190529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231006